PMID- 34330312
OWN - NLM
STAT- MEDLINE
DCOM- 20220125
LR  - 20220125
IS  - 1757-2215 (Electronic)
IS  - 1757-2215 (Linking)
VI  - 14
IP  - 1
DP  - 2021 Jul 31
TI  - Randomized double blind clinical trial evaluating the Ellagic acid effects on 
      insulin resistance, oxidative stress and sex hormones levels in women with 
      polycystic ovarian syndrome.
PG  - 100
LID - 10.1186/s13048-021-00849-2 [doi]
LID - 100
AB  - OBJECTIVE: The design of this study was due to the report of the antioxidant 
      properties of Ellagic acid (EA) for its evaluation on the Insulin resistance 
      (IR), oxidative stress and sex hormones levels in women with polycystic ovarian 
      syndrome (PCOS). METHODS: In this randomized, double-blind, placebo-controlled 
      clinical trial, 60 patients were recruited. Patients were randomly allocated 
      consumed a capsule containing 200 mg of EA per day (n = 30) or placebo (n = 30) 
      for 8 weeks. The fasting blood sugar (FBS), insulin, IR, total cholesterol (TC), 
      triglycerides (TG), low density lipoprotein (LDL), high density lipoprotein 
      (HDL), total antioxidant capacity (TAC), Malondialdehyde (MDA), C-reactive 
      protein (CRP), Tumor necrosis factor-alpha (TNF-alpha), sex hormones and 
      anti-mullerian hormone (AMH) were measured at the beginning and end of the study. 
      RESULT: At the end of the study, the mean of FBS, insulin, IR, TC, TG, LDL, MDA, 
      CRP, TNF-alpha, total testosterone, prolactin and AMH were significantly decreased in 
      the intervention group compared to the placebo group (P < 0.05). Also, there was 
      a significant increase in the mean of TAC after supplementation with EA 
      (P < 0.05). At the end of the study, no significant changes were observed in the 
      mean of anthropometric factors, physical activity and food intake (P > 0.05). 
      CONCLUSION: EA supplementation can be helpful as a diet supplement in women with 
      PCOS through improvement in insulin resistance. This supplement may be used to 
      reduce metabolic disorders in women. TRIAL REGISTRATION: This study was 
      retrospectively (07-07-2019) registered in the Iranian website ( www.irct.ir ) 
      for registration of clinical trials ( IRCT20141025019669N12 ).
CI  - (c) 2021. The Author(s).
FAU - Kazemi, Mahnaz
AU  - Kazemi M
AD  - Department of Nutrition, School of Health, Qazvin University of Medical Sciences, 
      Qazvin, Iran.
FAU - Lalooha, Fatemeh
AU  - Lalooha F
AUID- ORCID: 0000-0003-4241-7958
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Qazvin University 
      of Medical Sciences, Qazvin, Iran.
FAU - Nooshabadi, Mohammadreza Rashidi
AU  - Nooshabadi MR
AUID- ORCID: 0000-0002-1707-0094
AD  - Department of Pharmacology, School of Pharmacy, Ahvaz Jundishapur University of 
      Medical Sciences, Ahvaz, Iran.
FAU - Dashti, Fariba
AU  - Dashti F
AD  - Department of Nutrition, School of Health, Qazvin University of Medical Sciences, 
      Qazvin, Iran.
FAU - Kavianpour, Maria
AU  - Kavianpour M
AUID- ORCID: 0000-0002-8047-8754
AD  - Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, 
      Tehran University of Medical Sciences, Tehran, Iran. Kavianpour.maria@gmail.com.
FAU - Haghighian, Hossein Khadem
AU  - Haghighian HK
AUID- ORCID: 0000-0002-7445-1846
AD  - Metabolic Diseases Research Center, Research Institute for Prevention of 
      Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. 
      khademnut@yahoo.com.
AD  - Department of Nutrition, Faculty of Health Qazvin, University of Medical 
      Sciences, Qazvin, Iran. khademnut@yahoo.com.
LA  - eng
GR  - IR.QUMS.REC.1398.033/Qazvin University of Medical Sciences/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210731
PL  - England
TA  - J Ovarian Res
JT  - Journal of ovarian research
JID - 101474849
RN  - 0 (Gonadal Steroid Hormones)
RN  - 19YRN3ZS9P (Ellagic Acid)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Double-Blind Method
MH  - Ellagic Acid/pharmacology/*therapeutic use
MH  - Female
MH  - Gonadal Steroid Hormones/*immunology
MH  - Humans
MH  - Insulin Resistance/*immunology
MH  - Middle Aged
MH  - Oxidative Stress/*drug effects
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC8325180
OTO - NOTNLM
OT  - Anti-mullerian hormone
OT  - Ellagic acid
OT  - Insulin resistance
OT  - Polycystic ovarian syndrome
OT  - Stress oxidative
COIS- We wish to confirm that there are no known conflicts of interest associated with 
      this publication and there has been no significant financial support for this 
      work that could have influenced its outcome.
EDAT- 2021/08/01 06:00
MHDA- 2022/01/27 06:00
PMCR- 2021/07/31
CRDT- 2021/07/31 06:14
PHST- 2021/03/07 00:00 [received]
PHST- 2021/07/22 00:00 [accepted]
PHST- 2021/07/31 06:14 [entrez]
PHST- 2021/08/01 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/07/31 00:00 [pmc-release]
AID - 10.1186/s13048-021-00849-2 [pii]
AID - 849 [pii]
AID - 10.1186/s13048-021-00849-2 [doi]
PST - epublish
SO  - J Ovarian Res. 2021 Jul 31;14(1):100. doi: 10.1186/s13048-021-00849-2.